OMER News & Events

Sagimet Biosciences (SGMT) announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. Grauer most recently served as Chief Medical Officer at Omeros Corporation (OMER)

A month-long Middle East standoff which disrupted the flow of oil through the Strait of Hormuz and roiled investor sentiment for over a month appears to have finally found a path toward anofframp.  Reports citing the Islamic Republic News Agency that Iranian officials are prepared to discuss the terms of the end to the conflict sent U.S. equities sharply higher, with S&P 500 ending the day up nearly 3% and the Nasdaq up nearly 4%.  Beaten down Tech, Communication Services, and Materials sectors were the best performing areas of the market while Energy - the only sector to finish the month of March in the positive - retreated, with Oil prices falling sharply.In the opening hour of the evening session, S&P e-minis and Nasdaq 100 futures are little changed with consolidation of today's gains in spite of more macro headlines on the wires citing President Trump indicate that the conflict could rage another 2-3 weeks.Afterhours earnings session saw results from some notable names in the Consumer space - Nikewas down sharply despite topping Q3 estimates as the management's guidance for Q4 revenue was well short of consensus, while PVH Corp .and Dave and Bustersrallied after their Q4 results.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -nCinoup 18.6%Dave & Buster's Entertainmentup 4.9%Omerosup 4.6%PVH Corp.up 1.9%DOWN AFTER EARNINGS -RHdown 17.6%NIKEdown 9.2%Sportsman's Warehousedown 6.4%POET Technologiesdown 1.5%TruBridgedown 1.0%ALSO LOWER -ORIC Pharmaceuticalsdown 26.6% after ORIC-944 program update

Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth quarter also includes a $136.0 million non-cash charge associated with the mark-to-market adjustment on the embedded derivatives related to our 2029 Notes and Term Loan. Excluding the non-cash charge associated with the embedded derivatives, non-GAAP adjusted net income for the three months and year ended December 31, 2025 was $222.5 million, or $3.14 per share, and $133.4 million, or $2.10 per share, respectively. "In the fourth quarter of 2025, Omeros delivered transformative achievements for our shareholders," said Gregory A. Demopulos, CEO. "Following FDA approval of YARTEMLEA with a broad label and no boxed warning, REMS, or required vaccinations, our commercial launch is well underway, and patients who urgently need the drug are now able to access it. Our partnership with Novo Nordisk expands the breadth of indications being pursued for zaltenibart and has provided - and should continue to provide - substantial operating capital while underscoring the value of our science. These successes are expected to fuel the development of a growing portfolio of commercial products from our robust pipeline as we target positive cash flow in 2027."